Navigation Links
Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)

Results of international, multi-center registry presented at conference

NATICK, Mass., May 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that results from an international, multi-center patient registry documenting the safety and clinical utility of the SpyGlass(R) Direct Visualization System will be presented at Digestive Disease Week(R) (DDW), which runs from May 17-22 in San Diego, CA. Registry results will be announced in three separate scientific oral presentations scheduled for Tuesday, May 20. In addition, a total of 15 abstracts on the clinical utility of the SpyGlass System will be presented at the conference, underscoring its widespread acceptance in physician practices.

The SpyGlass patient registry reports on clinical data from 296 patients at 15 U.S. and European medical centers who required peroral cholangioscopy (PO) for the treatment or diagnosis of biliary stones or indeterminate strictures with suspected pathology.

The SpyGlass System is the first single-use direct visualization system that requires only a single physician operator and provides four-way steerability in a four lumen single-use catheter. The catheter provides two dedicated irrigation channels in addition to a 1.2 mm working channel through which diagnostic and therapeutic devices can be used in the biliary ducts. The system includes a miniature 6,000-pixel fiber optic probe attached to a camera that provides physicians with a direct view of a patient's bile ducts, overcoming some of the visual challenges of conventional endoscopic retrograde cholangiography (ERC) procedures.

"We are excited that DDW provides an opportunity to highlight the safety and therapeutic benefits of the SpyGlass System at the one-year anniversary of its worldwide launch," said Michael P. Phalen, President, Boston Scientific Endoscopy. "We have received positive feedback from the GI community regarding the ability of the SpyGlass System to provide excellent direct visual access to the bile ducts. We have nearly 300 patients enrolled in our comprehensive patient registry, which enables us to build further evidence of the clinical utility of cholangioscopy using the SpyGlass System." Schedule of SpyGlass Patient Registry Presentations:

Tuesday, May 20th (all times are PT)

-- Peroral Cholangioscopy Using a Disposable Steerable Single Operator

Catheter for Biliary Stone Therapy and Assessment of Indeterminate

Strictures - A Multi-Center Experience

Yang K. Chen, M.D., Division of Gastroenterology and Hepatology,

University of Colorado at Denver and Health Sciences Center, and

primary principal investigator of the SpyGlass registry, will present

results that document the performance and utility of PO using the

SpyGlass System over a 12-month period. The presentation will take

place at 4:00 p.m. in Room 1 at the San Diego Convention Center.

-- Peroral Cholangioscopy Guided Stone Therapy - Report of an

International Multi-Center Registry

Mansour Parsi, M.D., Department of Gastroenterology and Hepatology, The

Cleveland Clinic Foundation, and principal investigator in the SpyGlass

registry, will present results on a subset of patients that underwent

PO using the SpyGlass System to determine its effectiveness in the

treatment of difficult-to-remove biliary stones and assess its utility

for the detection of missed stones by ERC. The presentation will take

place at 4:36 p.m. in Room 1 at the San Diego Convention Center.

-- Biopsy of Indeterminate Biliary Strictures - Does Direct Visualization


Kenneth F. Binmoeller, M.D., Interventional Endoscopy Services,

California Pacific Medical Center, San Francisco, CA, and principal

investigator in the SpyGlass registry, will present results on a subset

of patients with indeterminate biliary strictures or filling defects

that underwent ERC followed by PO using the SpyGlass System and the

SpyBite(R) Biopsy Forceps. The lead author of the analysis is Douglas

Pleskow, M.D., Division of Gastroenterology, Beth Israel Deaconess

Medical Center, Boston, MA, and principal investigator in the SpyGlass

registry. The presentation will take place at 5:00 p.m. in Room 1 at

the San Diego Convention Center.

The SpyGlass Direct Visualization System will be available for demonstrations at Boston Scientific's booth #3314. The Company will also offer hands-on demonstration sessions in its Simulated Clinical Endoscopy Suite for the following products: WallFlex(R) Stents, Polyflex(R) Esophageal Stents, Radial Jaw(R) 4 Biopsy Forceps, Resolution(R) Clip, CRE(TM) Balloon Dilators and the RX Biliary System(TM).

About Digestive Disease Week(R)

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 17-22, 2008, at the San Diego Convention Center, San Diego, CA. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for less invasive, more efficient gastrointestinal procedures. We stand beside our physicians, surgeons and nurses, providing comprehensive support locally and through hands-on education and industry sponsorships, to help improve patient outcomes.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
4. Fraunhofer and Boston University Hosted Prestigious SME Tour
5. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
6. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
7. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
8. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
9. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
10. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
11. Boston Scientific Announces Japanese Approval of Heart Failure Lead
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):